A Eucomed survey estimates that the proposal to centralize the premarket approval process in Europe would cost medtech companies roughly $23 billion. Eucomed CEO Serge Bernasconi also expressed some concerns about the proposal, saying, "Not only will it kill the SME and innovation ecosystem in Europe with many jobs, it will also limit innovative treatment options being available to patients."

Related Summaries